Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_2
1
25%
Ph not_applicable
1
25%
Ph phase_1
2
50%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Completed2
Recruiting1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (50.0%)
Phase 21 (25.0%)
N/A1 (25.0%)

Trials by Status

recruiting125%
enrolling_by_invitation125%
completed250%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_1

NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits

NCT02994433
enrolling_by_invitationphase_1

Nitrous Oxide- Suicidal Ideation

NCT03736538
completednot_applicable

Hyperbaric Oxygen Therapy for Post-Concussion Syndrome

NCT05643482
completedphase_2

Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies

NCT03283670

Clinical Trials (4)

Showing 4 of 4 trials
NCT02994433Phase 1

NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits

Recruiting
NCT03736538Phase 1

Nitrous Oxide- Suicidal Ideation

Enrolling By Invitation
NCT05643482Not Applicable

Hyperbaric Oxygen Therapy for Post-Concussion Syndrome

Completed
NCT03283670Phase 2

Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4